InControl
This article was originally published in The Gray Sheet
Executive Summary
Redmond, Washington-based developer of the Metrix 3000 implantable atrial defibrillator announces that Invemed Associates, underwriters for its initial public offering, has exercised its over-allotment option to purchase $2.8 mil. in shares of common stock. Including the over-allotment, net proceeds from the offering, which was announced in July ("The Gray Sheet" July 18, p. 9), will be about $30.3 mil. Proceeds from the offering are pegged to fund research and development, clinical trials, and to establish European operations